CMMB · Chemomab Therapeutics Ltd.
$1.39
-0.01 (-0.71%)
At close · Jul 24
Market Cap
$9.97M
Shares
7.33M
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$1.40
Open$1.43
Day$1.38–1.49
52W$1.35–4.80
Avg vol 30d212K
Short int135K · 1.8% float · 1.0d
Short vol34%
Last earningsMay 11, 2023
DataJan 2020–Jul 2026
Filing10-Q · May 11
Up next
FQ3-26 quarter ends
~Sep 30, 2026
Est
filed May 11, 2023
Equibles Rating
blended score · not investment adviceOverall
Strong Sell
SellHoldBuy
Technical
Strong Sell
Momentum
Very Weak
Sentiment
Neutral
Fundamentals
Weak
Quant / Vol
Very High
Market backdrop
VIX 18.6 · elevated
Equity put/call 0.79
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
−30%
below
Price vs 50-day avg
−19%
below
RSI (14)
40
neutral
MACD trend
Negative
52-week position
1%
near low
Volume (OBV)
Confirms
volume backs price
Momentum
relative strength
1-month return
−10%
trailing
6-month return
−11%
trailing
YTD return
−15%
this year
Relative strength
−17%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $2 › 200d $2 — 200d above 50d
Institutional flow
Distributing
2 of 15 funds reported for Jun 30 · net -2.8K sh shares
Insider flow
Accumulating
Net +$20.2K over 90 days · 0% sells
Short interest
Falling
1.84% of float · ▼ -5.8% MoM · 1.0 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
15 holders — 13F breadth
Squeeze score
36
low risk · 0–100
Fundamentals
EPS growth
−54%
Y/Y
Free cash flow
$-11.1M
Balance sheet
$7.6M
net cash
Quant / Vol
risk profile
Volatility
88%
annualized · 1-yr
Max drawdown
−68%
past year
ATR
13.7%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders Strong Sell
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
−30%
Bearish
Price vs 50-day avg
−19%
Bearish
RSI (14)
40
Neutral
MACD trend
Negative
Bearish
52-week position
1%
Bearish
Volume (OBV)
Confirms
Neutral
Market signals — smart money & positioning
Bullish · 2 of 6
Trend (MA cross)
No cross
50d $2 › 200d $2 — 200d above 50d
Institutional flow
Distributing
2 of 15 funds reported for Jun 30 · net -2.8K sh shares
Insider flow
Accumulating
Net +$20.2K over 90 days · 0% sells
Short interest
Falling
1.84% of float · ▼ -5.8% MoM · 1.0 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
15 holders — 13F breadth
Price context
position in its 52-week range
52-wk low $1
Now $1 · 1%
52-wk high $5
vs 200-day avg -30%
vs 50-day avg -19%
Illustrative technical + ownership context — a signal mix, not investment advice.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
CMMB
this stock
Chemomab Therapeutics Ltd.
|
$9.97M | -15.2% | — | — | 1.8% |
|
ONC
BeOne Medicines Ltd.
|
$471.01B | +7.6% | +22179.2% | 958.5 | 0.1% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$121.16B | +4.4% | +46.2% | 28.3 | 2.0% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$68.78B | -15.4% | +20.8% | 16.0 | 3.3% |
|
ARGX
Argenx SE
|
$57.44B | +9.9% | — | — | 2.5% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Institutional Holders
Reducing
Holders
15
- % held
- 4.8%
- Reported
- 2 of 15
- Top holder
- ADAR1 Capital Management,…
Held
Float
Short & Settlement
Smart Money
Financials
Filings
Earnings & Events
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| CMMB | -7.9% | -9.7% | -10.8% | -13.6% | -15.2% |
| SPY | -1.7% | +0.7% | +6.4% | -1.2% | +8.3% |
| vs SPY | -6.2% | -10.4% | -17.2% | -12.4% | -23.4% |